ResMed Files Patent Infringement Action against Fisher & Paykel
ResMed (NYSE: RMD) (ASX: RMD), the world’s leading tech-driven medical device company and innovator in sleep apnea and respiratory care, today filed a petition with the United States International Trade Commission to stop the infringement of its patented technology by New Zealand-based medical device manufacturer Fisher & Paykel Healthcare.
In the International Trade Commission, ResMed seeks an order banning the importation and sale in the United States of Fisher & Paykel’s Simplus full face mask, Eson nasal mask and Eson 2 nasal mask, for infringing five ResMed patents relating to mask system and cushion design. ResMed’s new case asserts that:
- F&P’s Simplus infringes each of the five asserted ResMed patents.
- F&P’s Eson and Eson 2 infringe three of the five patents, which relate to modular mask systems.
Also today, ResMed filed a new lawsuit in the United States District Court for the Southern District of California, seeking monetary damages based on Fisher & Paykel’s patent infringement, plus an injunction against future sales of infringing masks in the United States.
“ResMed provides millions of consumers with high-quality products, which are the direct result of substantial and sustained investments in research and development, as well as a focus on each consumer’s therapy needs,” said ResMed global general counsel and chief administrative officer David Pendarvis. “We will defend our intellectual property wherever necessary to ensure that patients worldwide continue to receive the high-quality care they deserve, and are confident that when the ITC and the District Court hear all the evidence, ResMed will prevail in these cases.”
About ResMed
ResMed (NYSE: RMD, ASX: RMD) changes lives with award-winning medical devices and cloud-based software applications that better diagnose, treat and manage sleep apnea, chronic obstructive pulmonary disease (COPD) and other chronic diseases. ResMed is a global leader in connected care, with more than 5 million patients remotely monitored every day. Our 6,000-strong team is committed to creating the world’s best tech-driven medical device company – improving quality of life, reducing the impact of chronic disease, and saving healthcare costs in more than 120 countries. ResMed.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20180831005473/en/
Contact information
For media:
Jayme Rubenstein
+1 858.836.6798
news@resmed.com
or
For
investors:
Amy Wakeham
+1 858.836.5000
investorrelations@resmed.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Veridas Identity Fraud Solutions Now Available on AWS Marketplace21.8.2025 19:05:00 EEST | Press release
Veridas, a global leader in identity verification and biometric solutions, today announced that its Identity Verification (IDV) platformis now available on Amazon Web Services (AWS) Marketplace. This launch puts the full power of Veridas’ fraud prevention and identity verification capabilities in the hands of millions of AWS customers worldwide, making secure digital trust only a click away. As identity fraud rises exponentially — with threats from synthetic identities, deepfakes, and injection attacks — Veridas delivers a cloud-native solution combining facial biometrics, AI-driven document authentication, and certified liveness detection. The platform shields enterprises from fraud while enabling seamless onboarding in seconds. “Live since 2017, our IDV platform already protects more than 300 clients in 25 countries against advanced fraud such as deepfakes and injection attacks, with 100% proprietary technology, global coverage, and international compliance,” said Eduardo Azanza, CEO
Altasciences Chosen by Steel Therapeutics to Support the Launch of Pivotal Toxicology Study for Fizurex™21.8.2025 18:21:00 EEST | Press release
Altasciences is pleased to have been chosen by Steel Therapeutics, Inc. (“Steel”), to initiate a pivotal toxicology study for Fizurex™, a novel topical therapy for the treatment of anal fissures. The GLP-compliant study is currently being conducted at Altasciences’ preclinical facility in Columbia, MO. It marks a key milestone in Steel’s regulatory development, as the company prepares for an Investigational New Drug (IND) application in early 2026. “We’re proud to be supporting Steel Therapeutics at this key stage of their development journey,” said Steve Mason, Co-COO at Altasciences. “Our teams are aligned in their commitment to accelerate the delivery of patient-centered therapies. The initiation of this study is another example of how early collaboration and scientific rigor can bring important treatments closer to market.” Fizurex™, a patent-pending compounded wipe, has seen widespread use in clinical practice and is now progressing through the formal regulatory pathway to reach b
Media alert | Masdar receives ‘AA-’ credit rating with stable outlook by S&P Global Ratings in further recognition of the financial strength of the business21.8.2025 16:55:00 EEST | Press release
Masdar has been assigned an ‘AA-’ credit rating with a stable outlook by S&P Global Ratings, reinforcing its position as a global clean energy leader. This new rating reflects Masdar's diversified global position, strong growth prospects, and disciplined financial policies, including the allocation of green bond proceeds to finance the construction of new projects. With top credit ratings now secured from Moody’s (A1), Fitch (AA-) and S&P (AA-), Masdar continues to be recognized as one of the most financially robust renewable energy companies worldwide. This enables the Company to continue to drive responsible expansion and deliver inclusive progress across key international markets. The rating is also underpinned by the strong support of the Company's three shareholders - Abu Dhabi National Oil Company (ADNOC), Mubadala Investment Company, and Abu Dhabi National Energy Company PJSC (TAQA) - as well as the Government of Abu Dhabi. View source version on businesswire.com: https://www.bu
Andersen Consulting Expands Presence Through Collaboration with Ignis21.8.2025 16:30:00 EEST | Press release
Andersen Consulting adds depth to its strategy capabilities with collaborating firm Ignis, a leading media agency, reinforcing the organization’s commitment to delivering seamless solutions to clients globally. Founded in Buenos Aires, Ignis has earned a reputation for helping organizations build and achieve their brand objectives. With expertise in marketing communications strategy, market research, media planning and buying, and digital marketing, the firm works with companies in industries such as banking, insurance, and food and beverage across Latin America to drive brand growth, customer engagement, and measurable business results. “We’ve built Ignis with a spirit of entrepreneurship and bold thinking, and this collaboration enhances the global reach and resources to continue scaling that vision,” said Alejandro Terzi, chairman and founder of Ignis. “It opens new doors for innovation, fuels our ability to take on more ambitious challenges, and ultimately, allows us to deliver eve
Verb Technology Announces $780 Million in Treasury Assets to Advance its TON Treasury Strategy21.8.2025 16:20:00 EEST | Press release
Verb Technology Company, Inc. (Nasdaq: VERB) (to be renamed Ton Strategy Company) (the “Company”) today announced treasury assets exceeding $780 million, including $713 million1 of Toncoin ($TON), the native cryptocurrency of The Open Network (“TON”) Blockchain, and $67 million of cash. This is an important milestone in the Company’s implementation of its previously announced $TON treasury strategy. Today’s news follows the Company’s August 8 closing of a $558 million private placement joined by more than 110 institutional and crypto-native investors. The Company used the majority of proceeds from the private placement to acquire $TON as its primary treasury reserve asset. "Crossing $780 million in assets just days after our private placement reflects the conviction behind $TON,” said Manuel Stotz, Executive Chairman of the Company. “This is more than building a balance sheet; it’s about contributing to the security of TON blockchain – where participants can build, transact, and benefi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom